Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lupus Vulgaris | IND Application | CN | 11 Oct 2023 | |
Non-Hodgkin Lymphoma | IND Application | CN | 11 Oct 2023 |